Stocktoria
ATOSSA THERAPEUTICS, INC. ATOS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2012-11-08
ATOSSA THERAPEUTICS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $21.2M | $14.1M | $17.3M | $15.1M | $9.2M |
| Operating income | -$37.1M | -$27.6M | -$31.4M | -$27.7M | -$20.5M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$34.8M | -$25.5M | -$30.1M | -$27.0M | -$20.6M |
| EPS (diluted) | $-4.04 | $-3.04 | $-0.24 | $-0.21 | — |
| Operating cash flow | -$29.8M | -$21.0M | -$20.9M | -$20.8M | -$16.5M |
| Free cash flow | -$29.8M | -$21.0M | -$21.0M | -$20.8M | -$16.5M |
| Cash & equivalents | $41.3M | $71.1M | $88.5M | $110.9M | $136.4M |
| Total assets | $47.6M | $76.4M | $96.3M | $123.5M | $141.3M |
| Total liabilities | $8.3M | $5.0M | $5.2M | $5.6M | $3.1M |
| Shareholders' equity | $39.4M | $71.5M | $91.0M | $118.0M | $138.1M |
Source: SEC EDGAR filings · CIK 0001488039 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.